Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.
about
Regulation of endothelial homeostasis, vascular development and angiogenesis by the transcription factor ERGEmerging Role of Genomic Rearrangements in Breast Cancer: Applying Knowledge from Other CancersMatrin3: connecting gene expression with the nuclear matrixTargeting the ubiquitin pathway for cancer treatmentTargeting the adaptive molecular landscape of castration-resistant prostate cancerLa FAM fatale: USP9X in development and diseaseDeubiquitinase inhibition by WP1130 leads to ULK1 aggregation and blockade of autophagyUSP9X regulates centrosome duplication and promotes breast carcinogenesis.Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinomaMolecular pathways and targets in prostate cancerEPI-001 is a selective peroxisome proliferator-activated receptor-gamma modulator with inhibitory effects on androgen receptor expression and activity in prostate cancerThe ETS family of oncogenic transcription factors in solid tumours.Deubiquitinases in cancer.Combined inhibition of Bcl-2/Bcl-xL and Usp9X/Bag3 overcomes apoptotic resistance in glioblastoma in vitro and in vivo.Role of Angiomotin-like 2 mono-ubiquitination on YAP inhibition.Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.Inhibition of deubiquitinases primes glioblastoma cells to apoptosis in vitro and in vivo.USP9X stabilizes XIAP to regulate mitotic cell death and chemoresistance in aggressive B-cell lymphoma.Arginine methylation of USP9X promotes its interaction with TDRD3 and its anti-apoptotic activities in breast cancer cells.USP9X destabilizes pVHL and promotes cell proliferation.The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer.Androgen receptor and gene network: Micromechanics reassemble the signaling machinery of TMPRSS2-ERG positive prostate cancer cells.The oncogene ERG: a key factor in prostate cancer.Systematic enrichment analysis of potentially functional regions for 103 prostate cancer risk-associated loci.Decision for cell fate: deubiquitinating enzymes in cell cycle checkpoint.The X-linked deubiquitinase USP9X is an integral component of centrosome.Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.SPOP Promotes Ubiquitination and Degradation of the ERG Oncoprotein to Suppress Prostate Cancer Progression.Drug discovery in advanced prostate cancer: translating biology into therapy.Targeting Deubiquitinating Enzymes in Glioblastoma Multiforme: Expectations and Challenges.Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate CancerThe Spliceosomal Protein SF3B5 is a Novel Component of Drosophila SAGA that Functions in Gene Expression Independent of Splicing.Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma.Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer.Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.Ethnicity and ERG frequency in prostate cancer.Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth.USP9X controls translation efficiency via deubiquitination of eukaryotic translation initiation factor 4A1.Stabilization of the methyl-CpG binding protein ZBTB38 by the deubiquitinase USP9X limits the occurrence and toxicity of oxidative stress in human cells.
P2860
Q26747155-EC67DD9E-9BD8-437E-A8DB-A81EF4144D41Q26766271-26C81369-6C8A-4FA4-B796-6DDC293DE772Q26774243-C3C56D64-B38A-4E7F-891B-EBA456A72389Q26866185-7B7751F3-9B16-4907-BB5B-04B527C9ABC3Q27022821-B37B3BB4-639E-4F09-809A-81269A8B172EQ27025293-3E9F4DDF-5AEB-4869-B9C5-55F882120D74Q27311286-32D17EC3-F953-449F-A49B-0908939E5BE9Q30844123-9DE549C2-5C51-41D6-8295-9197F3DA1568Q33989933-26B07738-C37B-4259-A1A4-1A10312B2C28Q34365632-E0016569-9D0D-47C3-A1DF-E3F6722E6C32Q34462138-700E526B-9948-42D8-9E82-A81230966A12Q34555986-AE4EE994-1EAE-4FB6-A349-9F6E8769D91CQ35955141-94B27C29-C978-4639-8936-FF4D3827D459Q35987399-0102596A-9D31-4685-A1A8-856298A25C92Q36478653-065C644D-ADFD-40ED-A6A2-89148CF84C31Q36545843-399CB17A-6AA0-4AE0-AD2D-329145788748Q36546689-EAA83765-C4FC-4B3A-85E9-2C761C2ECB53Q37022290-3D40267A-C5BA-4831-BCFC-ED1A939E3D7FQ37141364-BFE2250F-AF29-4E53-96A6-8CA92B0F8F71Q37550449-FEE7E104-9885-494B-A9C0-150CD9D52F8BQ37645058-1BC5CDE7-7700-4CFE-B3A4-E4A2B0AE1AF2Q37662159-BEB7FD13-3640-433E-9343-F57A88790C4FQ37727814-C9499284-3082-4F6F-A216-B32E4993413CQ38444138-05EA2B84-4256-410C-B6DC-E679AEFBFE7AQ38503798-9E81628F-F6BD-4433-8404-5B27F0B540FAQ38695071-63D12327-78BC-49A1-8D87-C4AAFA8FD9B2Q38700147-F5BD4BFA-E41C-4E59-A08B-002A0B2D13BEQ38710470-DC3622CD-BEC6-491B-A388-268F1A0D68D8Q38837458-64297629-27EF-438C-9627-FF7B17B93B15Q38839110-30D4EA2C-3D4B-4043-BE5B-D6530B9275D9Q38989377-0F4F3718-3AA9-4670-8F2F-3A85E193ECC3Q39164084-F022B2A7-68D8-442E-AEF3-F5EAFA217732Q39761741-9A59C252-CD61-4541-BEBD-0B0B0C4F87EDQ42320717-08C9CC3E-8CD5-4DCD-A534-35A3AF15B31EQ42335698-53DE763D-0F02-4D07-BFBC-B56CA43C91FCQ45233800-FB7F1DD9-2657-4CEA-93C3-FFA4A14692F5Q46504038-CF8CD7EF-250E-4FBE-A325-BA29B3ECEB46Q47150678-6BF0221C-1B23-46EB-87A0-97AABD55D0C0Q47307244-CA609140-82B4-4F69-B710-16800524A2FFQ52681296-7878813F-599F-43A5-9D64-763A503753CF
P2860
Ablation of the oncogenic transcription factor ERG by deubiquitinase inhibition in prostate cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 March 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Ablation of the oncogenic tran ...... inhibition in prostate cancer.
@en
Ablation of the oncogenic tran ...... inhibition in prostate cancer.
@nl
type
label
Ablation of the oncogenic tran ...... inhibition in prostate cancer.
@en
Ablation of the oncogenic tran ...... inhibition in prostate cancer.
@nl
prefLabel
Ablation of the oncogenic tran ...... inhibition in prostate cancer.
@en
Ablation of the oncogenic tran ...... inhibition in prostate cancer.
@nl
P2093
P2860
P356
P1476
Ablation of the oncogenic tran ...... inhibition in prostate cancer.
@en
P2093
Caroline G Humphries
Elizabeth Hernandez
Eva Freeman
Ganesh V Raj
Jer-Tsong Hsieh
Ladan Fazli
Martin E Gleave
Nishi Srivastava
Payal Kapur
Preethi Ravindranathan
P2860
P304
P356
10.1073/PNAS.1322198111
P407
P50
P577
2014-03-03T00:00:00Z